Retrospective Review on Safety and Efficacy of Combination Biologic Therapy for Psoriasis

There is limited data on the use of dual or combination biologic therapy in dermatological patients, particularly in psoriasis or with other coexisting dermatological conditions. However, this may be necessary for a small proportion of patients.

We conducted a retrospective review of 46 patients treated with dual or combination biologic therapy at a single dermatology practice in Sydney, Australia. The patient cohort consisted of 44 patients with psoriasis, 1 patient with hidradenitis suppurativa and 1 patient with a combination of hidradenitis suppurativa and psoriasis.

Of 46 patients receiving a combination of biological agents, only 1 experienced an adverse effect that did not require cessation of therapy.

The use of combination biologic therapy may be an option for psoriasis patients with recalcitrant disease, in particular for those with concomitant psoriatic arthritis or other dermatological conditions. However, further studies are warranted to evaluate the efficacy, safety and health economics of this treatment approach.